T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024
T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024
LEXINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the first quarter 2024 and business updates after market close on Monday, May 6, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
马萨诸塞州列克星敦，2024年4月24日（GLOBE NEWSWIRE）——败血症致病原体和抗生素耐药基因快速检测领域的领导者T2 Biosystems, Inc.（纳斯达克股票代码：TTOO）今天宣布，将在2024年5月6日星期一收盘后公布2024年第一季度的财务业绩和业务最新情况。公司管理层将从美国东部时间下午 4:30 开始举行相应的电话会议。
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International), passcode 160751, approximately ten to five minutes prior to the start time.
有兴趣收听电话会议的投资者可以通过访问该活动的直播和存档网络直播来收听电话会议 www.t2biosystems.com，在 “活动和演示” 部分的 “投资者” 页面上。要收听电话会议，请在开始时间前大约十到五分钟拨打 1-888-506-0062（美国/加拿大）或 1-973-528-0011（国际），密码为160751。
About T2 Biosystems
关于 T2 生物系统
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems' products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance (T2MR) technology. T2 Biosystems has an active pipeline of future products, including the U.S. T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. For more information, please visit www.t2biosystems.com.
T2 Biosystems是快速检测诱发败血症的病原体和抗生素耐药基因领域的领导者，致力于通过帮助临床医生比以往任何时候都更快地有效治疗患者来改善患者护理和降低护理成本。T2 Biosystems 的产品包括 T2Dx 仪器，T2Bertia 小组，T2Candida 面板，T2Restance 面板和 T2Biothreat Panel，由专有的 T2 磁共振 (T2MR) 提供动力) 技术。T2 Biosystems 拥有活跃的未来产品线，包括美国的 T2Resistance 小组、 耳念珠菌 测试，以及 T2Lyme 小组。欲了解更多信息，请访问 www.t2biosystems.com。
投资者联系人：
菲利普·特里普泰勒，吉尔马丁集团
ir@T2Biosystems.com415-937-5406
Source: T2 Biosystems, Inc.
来源：T2 Biosystems, Inc.